Home / nuclear medicine

nuclear medicine

September 15, 2025

Translation of PET radiotracers and innovative analysis methods to the clinic in the era of total body PET

This article provides a comprehensive overview of the evolution and future potential of PET imaging, particularly in the context of total body PET technology. PET has evolved dramatically since its inception in the 1950s, advancing from basic scanners to sophisticated total body PET systems. These innovations, alongside the development of more selective radiotracers, have significantly […]

Professor Adriana Tavares

The University of Edinburgh

Read Article

April 28, 2025

Total body PET imaging: the changing radionuclide imaging landscape in the UK

Non-invasive radionuclide imaging has transformed clinical practice through enabling earlier diagnosis than before, more comprehensive staging, and monitoring of disease progression and therapy response. The quantitative nature of PET and widespread availability of standard radiopharmaceuticals, in particular [18F]FDG, have contributed to PET’s success. However, until recently, in order to capture information ‘from eyes to thighs’, […]

Professor Alexander Hammers; Dr Samantha Terry

King's College London

Read Article

April 28, 2025

An overview of CZT technology

The gamma camera has been a stalwart of nuclear medicine for many years. First described in 1958 by Hal Anger, the gamma camera is still the most used instrument for nuclear medicine imaging studies. While the transition to rotating tomographic SPECT systems and the incorporation of CT for SPECT attenuation correction and localisation has changed […]

Professor John C Dickson

University College London Hospitals NHS Foundation Trust

Read Article

October 16, 2024

Motion in myocardial perfusion PET

Myocardial perfusion PET is a well established technique for assessing obstructive coronary artery and coronary microvascular diseases. It has been shown to be superior to SPECT imaging in image quality, prognostic information, scan time and lower radiation dose for both the patient and operators. Through the creation of dynamic images, PET also provides the ability […]

Dr Ian Armstrong

Manchester University NHS Foundation Trust

Read Article

October 16, 2024

PSMA PET scanning in practice

Prostate cancer is the second most common cancer in the world, predicted to rise by 15% by 2025, while detection in late stage disease increased from 3.9% to 8.2% over the past decade in the USA. Primary investigations for clinical diagnosis and staging of prostate cancer include blood tests, biopsy and imaging techniques such as […]

Rayjanah Allie, Dr Dimitris Priftakis, Professor Jamshed Bomanji

University College London Hospitals NHS Foundation Trust

Read Article

May 15, 2024

Radioiodine ablation – current trends and controversies

Management for differentiated thyroid cancer (DTC) has seen significant changes over the last decade. The approach is dramatically shifting to personalised based rational decisions. This includes, but is not limited to, the extent of surgery, active surveillance in low risk very limited disease, radioiodine (RAI) ablation or no ablation after initial surgery, low iodine activity […]

Dr Fahim Ul Hassan

Guy's and St Thomas' NHS Foundation Trust

Read Article

May 15, 2024

The role of the consultant radiographer in molecular radiotherapy

The decision by departments and NHS trusts/boards to identify service requirements for consultant radiographers in molecular radiotherapy (MRT) is essential. Service needs should be patient centred, and the creation of a consultant radiographer post must be driven by the intention to offer the highest standards of patient care and to improve the patient care pathway, […]

Jo Weekes

New Cross Hospital

Read Article

October 11, 2023

Nuclear medicine theragnostics: walk before you run

Theragnostic nuclear medicine is a much discussed topic in nuclear medicine and is currently discussed and debated in clinical oncology with great interest and optimism. Radionuclide theragnostics generally pairs diagnostic biomarkers with radiolabelled therapeutic agents that share a specific target within the diseased cells or tissues. The clinical indications are expanding, with evolving evidence. Incorporating […]